Brief: Targinta Presents Positive Preclinical Data

Xintela AB

01/09/2022 16:02

Sept 1 (Reuters) - Xintela AB  XINT.ST :
    * TARGINTA PRESENTS POSITIVE PRECLINICAL DATA ON THE
ANTIBODY-DRUG
CONJUGATE TARG9
    * TARGINTA, A WHOLLY OWNED SUBSIDIARY OF XINTELA AB (PUBL),
PRESENTS NEW PRECLINICAL DATA ON ANTIBODY-DRUG CONJUGATE TARG9
AT 2ND INTEGRIN-TARGETED DRUG DEVELOPMENT SUMMIT, BOSTON

Source text for Eikon:  ID:nMFN2nywyf 
Further company coverage:  XINT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))